ATE292982T1 - Analgesiche synergie durch gleichzeitige verabreichung von subanalgesichen doseneines mu- opioidanagonisten und eines kappa - 2- opioidanagonisten - Google Patents

Analgesiche synergie durch gleichzeitige verabreichung von subanalgesichen doseneines mu- opioidanagonisten und eines kappa - 2- opioidanagonisten

Info

Publication number
ATE292982T1
ATE292982T1 AT96933277T AT96933277T ATE292982T1 AT E292982 T1 ATE292982 T1 AT E292982T1 AT 96933277 T AT96933277 T AT 96933277T AT 96933277 T AT96933277 T AT 96933277T AT E292982 T1 ATE292982 T1 AT E292982T1
Authority
AT
Austria
Prior art keywords
opioid
anagonist
analgesic
kappa
simultaneous administration
Prior art date
Application number
AT96933277T
Other languages
English (en)
Inventor
Maree Smith
Fraser Ross
Original Assignee
Univ Queensland
Lynx Project Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Queensland, Lynx Project Ltd filed Critical Univ Queensland
Application granted granted Critical
Publication of ATE292982T1 publication Critical patent/ATE292982T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT96933277T 1995-10-19 1996-10-21 Analgesiche synergie durch gleichzeitige verabreichung von subanalgesichen doseneines mu- opioidanagonisten und eines kappa - 2- opioidanagonisten ATE292982T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPN6038A AUPN603895A0 (en) 1995-10-19 1995-10-19 Production of analgesic synergy by co-administration of sub-analgesic doses of two strong opioids
PCT/AU1996/000656 WO1997014438A1 (en) 1995-10-19 1996-10-21 Production of analgesic synergy by co-administration of sub-analgesic doses of a mu opioid agonist and a kappa-2 opioid agonist

Publications (1)

Publication Number Publication Date
ATE292982T1 true ATE292982T1 (de) 2005-04-15

Family

ID=3790365

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96933277T ATE292982T1 (de) 1995-10-19 1996-10-21 Analgesiche synergie durch gleichzeitige verabreichung von subanalgesichen doseneines mu- opioidanagonisten und eines kappa - 2- opioidanagonisten

Country Status (13)

Country Link
US (1) US6310072B1 (de)
EP (1) EP0871488B1 (de)
JP (1) JP4571236B2 (de)
CN (1) CN1104910C (de)
AT (1) ATE292982T1 (de)
AU (2) AUPN603895A0 (de)
CA (1) CA2235375C (de)
DE (1) DE69634609T2 (de)
DK (1) DK0871488T3 (de)
ES (1) ES2241003T3 (de)
NZ (1) NZ319531A (de)
WO (1) WO1997014438A1 (de)
ZA (1) ZA968808B (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2266564B1 (de) 1997-12-22 2013-03-13 Euro-Celtique S.A. Peroral zu verabreichende Arzneiform enthaltend eine Kombination von einem opioid Agonisten und einem opioid Antagonisten
US6375957B1 (en) * 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
US6759520B1 (en) * 1999-10-28 2004-07-06 The New England Medical Center Hospitals, Inc. Chimeric analgesic peptides
SI1307194T2 (sl) * 2000-07-31 2011-07-29 Nycomed Danmark Aps Sestavek fentanila za nazalno dejanje
JP4522652B2 (ja) 2001-05-11 2010-08-11 エンドー ファーマシューティカルズ， インコーポレイティド 乱用防止制御放出オピオイド投薬形態
CA2778114A1 (en) * 2001-05-11 2002-11-21 Endo Pharmaceuticals, Inc. Abuse-resistant opioid dosage form
US7968119B2 (en) * 2001-06-26 2011-06-28 Farrell John J Tamper-proof narcotic delivery system
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
AU2003219680A1 (en) * 2002-01-23 2003-09-02 The Regents Of The University Of California Methods and compositions for reducing the development of drug tolerance and/or physical dependence
US20060177381A1 (en) * 2002-02-15 2006-08-10 Howard Brooks-Korn Opiopathies
LT2425824T (lt) 2002-04-05 2017-07-25 Euro-Celtique S.A. Farmacinis preparatas, turintis oksikodono ir naloksono
US20030199496A1 (en) * 2002-04-22 2003-10-23 Simon David Lew Pharmaceutical compositions containing alpha3beta4 nicotinic receptor antagonists and methods of their use
US6881829B2 (en) * 2002-04-26 2005-04-19 Chimeracom, L.L.C. Chimeric hybrid analgesics
US8557291B2 (en) 2002-07-05 2013-10-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opioids and other drugs
US10004729B2 (en) 2002-07-05 2018-06-26 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
CA2491572C (en) * 2002-07-05 2010-03-23 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opiods and other drugs
US8840928B2 (en) 2002-07-05 2014-09-23 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
WO2004016167A1 (en) * 2002-08-16 2004-02-26 The General Hospital Corporation Non-invasive functional imaging of peripheral nervous system activation in humans and animals
US20060178354A1 (en) * 2003-02-27 2006-08-10 Lucas John M Methods and compositions for the treatment of chronic pain using dhea and derivatives thereof
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
US20050053659A1 (en) * 2003-09-10 2005-03-10 Pace Gary W. Methods and compositions for reducing the risk associated with the administration of opioid analgesics in patients with diagnosed or undiagnosed respiratory illness
US7201920B2 (en) * 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
US20050251442A1 (en) * 2004-05-07 2005-11-10 Joseph Ficalora Consumer incentive system and business method
EP1604666A1 (de) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioide zur Behandlung der chronischen obstruktiven Lungenkrankheit
DK1765292T3 (en) 2004-06-12 2018-01-02 Collegium Pharmaceutical Inc ABUSE PREVENTIONAL PHARMACEUTICAL FORMULATIONS
EP1702558A1 (de) 2005-02-28 2006-09-20 Euro-Celtique S.A. Verfahren und Vorrichtung zur Darmtätigkeitserfassung
WO2007005716A2 (en) * 2005-06-30 2007-01-11 Cinergen, Llc Methods of treatment and compositions for use thereof
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8753308B2 (en) 2006-01-06 2014-06-17 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8202535B2 (en) 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US8252328B2 (en) * 2006-01-06 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US9066847B2 (en) * 2007-01-05 2015-06-30 Aceirx Pharmaceuticals, Inc. Storage and dispensing devices for administration of oral transmucosal dosage forms
US9289583B2 (en) 2006-01-06 2016-03-22 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8357114B2 (en) 2006-01-06 2013-01-22 Acelrx Pharmaceuticals, Inc. Drug dispensing device with flexible push rod
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
WO2007139826A2 (en) * 2006-05-26 2007-12-06 Cara Therapeutics, Inc. Method for elevating prolactin in mammals
US20080220062A1 (en) * 2006-10-23 2008-09-11 Psivida, Inc. Sustained release of agents for localized pain management
KR101445891B1 (ko) * 2007-01-05 2014-10-02 아셀알엑스 파마슈티컬스 인코퍼레이티드 경구 경점막 제형의 투여를 위한 저장 및 분배 장치
JP5965583B2 (ja) 2007-08-13 2016-08-10 インスピリオン デリバリー テクノロジーズ エルエルシー 乱用抵抗性医薬組成物、その使用方法および作製方法
WO2009143209A1 (en) * 2008-05-20 2009-11-26 Qrxpharma Limited Dual opioid pain therapy
US8945592B2 (en) 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
TWI630208B (zh) 2008-12-08 2018-07-21 歐陸斯迪公司 二氫羥戊甲嗎啡
HUE042105T2 (hu) 2009-03-10 2019-06-28 Euro Celtique Sa Oxikodont és naloxont tartalmazó azonnali hatóanyagleadású orális gyógyászati készítmények
WO2010107761A1 (en) 2009-03-18 2010-09-23 Acelrx Pharmaceuticals, Inc. Improved storage and dispensing devices for administration of oral transmucosal dosage forms
US20110046173A1 (en) * 2009-08-24 2011-02-24 Warren Charles Stern Combination analgesic opioid pain therapy
US8012990B2 (en) * 2009-10-14 2011-09-06 QRxPharma Ltd. Methods of converting a patient's treatment regimen from intravenous administration of an opioid to oral co-administration of morphine and oxycodone using a dosing algorithm to provide analgesia
US8222267B2 (en) 2009-10-14 2012-07-17 QRxPharma Ltd. Methods of converting a patient's treatment regimen from intravenous administration of an opioid to oral co-administration of morphine and oxycodone using a dosing algorithm to provide analgesia
US7923453B1 (en) 2009-10-14 2011-04-12 QRxPharma Ltd. Methods of converting a patient's treatment regimen from intravenous administration of an opioid to oral co-administration of morphine and oxycodone using a dosing algorithm to provide analgesia
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US8461171B2 (en) 2010-02-09 2013-06-11 QRxPharma Ltd. Hybrid opioid compounds and compositions
WO2012037239A1 (en) 2010-09-14 2012-03-22 QRxPharma Ltd. Methods of converting a patient's treatment regimen from intravenous administration of an opioid to oral co-administration of morphine and oxycodone using a dosing algorithm to provide analgesia
CA2907428A1 (en) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method
EP3024461B1 (de) 2013-07-23 2020-05-13 Euro-Celtique S.A. Kombination aus oxycodon und naloxon für die verwendung bei der behandlung von schmerzen bei patienten mit schmerzen und einer krankheit, die zur intestinaldysbiose und/oder erhöhung der gefahr bakterieller translokation führt
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
WO2016106329A1 (en) 2014-12-23 2016-06-30 Acelrx Pharmaceuticals, Inc. Systems, devices and methods for dispensing oral transmucosal dosage forms
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
US20210128549A1 (en) * 2018-02-28 2021-05-06 Celista Pharmaceuticals Llc Oxycodone and methylnaltrexone multiparticulates and suspensions containing them

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993002707A1 (de) * 1991-08-06 1993-02-18 Byk Gulden Lomberg Chemische Fabrik Gmbh Neue antidiarrhoica
US5273760A (en) * 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
IE940292A1 (en) * 1994-04-06 1995-10-18 Elan Corp Plc Biodegradable microcapsules and method for their manufacture

Also Published As

Publication number Publication date
JP4571236B2 (ja) 2010-10-27
AUPN603895A0 (en) 1995-11-09
CA2235375C (en) 2008-01-08
DK0871488T3 (da) 2005-08-15
ZA968808B (en) 1997-05-27
EP0871488A1 (de) 1998-10-21
JP2000511158A (ja) 2000-08-29
CA2235375A1 (en) 1997-04-24
NZ319531A (en) 1999-11-29
US6310072B1 (en) 2001-10-30
EP0871488B1 (de) 2005-04-13
DE69634609T2 (de) 2006-02-02
CN1104910C (zh) 2003-04-09
CN1204264A (zh) 1999-01-06
EP0871488A4 (de) 2001-04-04
AU706691B2 (en) 1999-06-24
WO1997014438A1 (en) 1997-04-24
ES2241003T3 (es) 2005-10-16
DE69634609D1 (de) 2005-05-19
AU7207696A (en) 1997-05-07

Similar Documents

Publication Publication Date Title
ATE292982T1 (de) Analgesiche synergie durch gleichzeitige verabreichung von subanalgesichen doseneines mu- opioidanagonisten und eines kappa - 2- opioidanagonisten
NZ508526A (en) Opioid formulations for treating pain
EP1201241A3 (de) Zusammensetzungen enthaltend Capsaicin oder seine Analogen und Lokalanästhetika
ATE293458T1 (de) Antikonvulsive mitteln enthaltende zubereitung zur behandlung von neuropathischen schmerzen
ES2295609T3 (es) Derivados de tiadiazolilpiperazina utiles para tratar o prevenir un dolor.
RU94027680A (ru) Паращитовидный гормон и ралоксифон для увеличения массы кости, фармацевтический состав и способ увеличения костной массы
ATE119386T1 (de) Äusserlich anzuwendende analgetische lotion und verfahren zur herstellung.
WO1994008551A3 (en) Pharmaceutical compositions and methods for treating cold symptoms
CY1107262T1 (el) Θεραπεια της εξαρτησης στερησης
BG106221A (bg) Назални фармацевтични препарати съдържащи морфин и методи на приложението им
KR930702000A (ko) 노년기 치매, 식용항진, 편두통, 또는 식용불량의 치료를 위한 파로세틴의 사용
SE0002754D0 (sv) New pharmaceutical combination formulation and method of treatment with the combination
NO925038L (no) Anordning for nedsettelse av medikamentets hudirriterendevirkninger
RU95101385A (ru) Продукты, содержащие g-csf и tnf связующие протеина
US5187177A (en) Method and a pharmaceutical preparation for treating pain
EP0813409A4 (de) Behandlung von erkrankungen, die vom cytokinwachstumsfaktor verursacht werden
MY124465A (en) Reduction of infarct volume using citicoline
BR0307022A (pt) Método de tratamento de um paciente que precisa de analgesia
EE03205B1 (et) Ropivakaiini kasutamine valuvaigistina kasutatava ravimpreparaadi valmistamiseks
Lao et al. Electroacupuncture reduces morphine-induced emesis in ferrets: a pilot study
SE8802564D0 (sv) New synergistic preparations and a new method of alleviation of pain
Tekol et al. Ephedrine diminishes some side effects of morphine
KR930007452A (ko) 벤조디아제핀-금단 환자의 불안증 치료방법
KR920700041A (ko) 치료화합물과 그의 조성 및 용도
TH60393A (th) การบัดบัดรักษาอาการเจ็บปวด

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties